M Pharmaceutical Inc.

M Pharmaceutical Inc.

August 19, 2015 10:05 ET

Matthew B. Lehman Appointed Chief Executive Officer of M Pharmaceutical, Inc.

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Aug. 19, 2015) - M Pharmaceutical, Inc. (CSE:MQ)(OTCQB:MPHMF)(FRANKFURT:T3F2), (the "Company"), a clinical-stage company developing innovative technologies for the monitoring and treatment of obesity, diabetes, and other gastroenterological indications, today announced the appointment of Matthew B. Lehman as President and Chief Executive Officer, effective September 1, 2015. Mr. Lehman brings over 15 years of executive level experience in the development of therapeutics to his new role. Dr. Martin Mintchev, the lead inventor of the Company's technologies and Company co-founder, will transition from his position as CEO to serve as Chief Scientific Officer.

"I am pleased to join M Pharmaceutical at this crucial time as we plan for the clinical development and global commercialization of our products," said Mr. Lehman. "Dr. Mintchev and his team have set a great foundation with innovative technologies and strong patent protection. I look forward to working with Dr. Mintchev to expedite development of the Trimeo Weight Loss Capsules, Trimtec Gastric Neurotimulation System, and eMosquito Wearable Blood Monitor."

"Mr. Lehman brings the Company the needed skills and experience to carry our innovative biomedical technologies to the world-wide marketplace and lead the Company's development," said Board Director George Tsafalas. "I would like to thank Dr. Mintchev for his service as the Company's founding CEO during our start-up stage and I am pleased that he will continue to serve as the Company's Chief Scientific Officer."

Mr. Lehman will be based in the Cincinnati, Ohio area, where the Company expects to establish its U.S. operating presence and focus on the Company's most important global market. In various roles of increasing responsibility in the U.S., Germany, Australia, and Ukraine, Mr. Lehman has significant global experience in clinical development, regulatory strategy, intellectual property management, negotiating grants and incentives, and raising capital for R&D stage companies. Most recently, Mr. Lehman was the CEO of Prima Biomed Ltd., a dual-listed public company (NASDAQ and ASX) developing cancer immunotherapies, where he obtained "Fast Track" from the FDA and "Orphan Drug" designation for Prima Biomed's lead product at the time. He is a graduate of Columbia University (M.S.) and University of Louisville (B.A.).

As of September 1, 2015, Mr. Lehman will also be appointed to the Company's Board of Directors.

About M Pharmaceutical Inc.

Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for the monitoring and treatment of obesity, diabetes, and other gastroenterological indications. The Company has exclusive rights to three technologies: (1) Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity; (2) Trimtec, gastrointestinal neurostimulators implanted laparoscopically for the treatment of obesity and gastroparesis without permanent anatomical modification of the stomach; and (3) eMosquito wearable blood monitor, for automatic and autonomous monitoring of blood glucose by diabetics.

M Pharmaceutical trades on the Canadian Securities Exchange (CSE) under the ticker symbol "MQ" as well as on the OTCQB as "MPHMF" and FWB (Frankfurt Stock Exchange) as "T3F2."

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the commercialization of the rights to the eMosquito, Trimeo and Trimtec biomedical technologies. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and the Company's filings to the CSE at www.cnsx.ca. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.

Notice regarding investigational devices: Trimeo, Trimtec, and eMosquito are investigational devices and are not currently available outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.

Contact Information